Day One Biopharmaceuticals Inc
Abierto
SectorSanidad
21.45
Resumen
Variación precio
24h
Mínimo
Máximo
Ingresos | -1.6M -21M |
|---|---|
Ventas | 14M 54M |
Margen de beneficios | -39.611 |
Empleados | 178 |
EBITDA | -7.7M -26M |
Recomendaciones | Neutral |
|---|---|
Estimación a 12 Meses | -3.62% downside |
Capitalización Mercado | 1B 2.2B |
|---|---|
Apertura anterior | 21.45 |
Cierre anterior | 21.45 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
143 / 342 Clasificación en Healthcare
Day One Biopharmaceuticals Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.